Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications

Breast Cancer

Volumn 24, Issue 2, 2017, Pages 220-228

  Yang, Jiqiao ^a   Tan, Qiuwen ^a   Fu, Qingyu ^a   Zhou, Yaojie ^a   Hu, Yuanyuan ^a   Tang, Shenli ^a   Zhou, Yuting ^a   Zhang, Junhui ^a   Qiu, Juanjuan ^a   Lv, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; Clinical prospect; Diet; Estrogens; Gastrointestinal microbiome

Indexed keywords

ANTIBIOTIC AGENT; ENTEROLACTONE; ESTROGEN; PHYTOESTROGEN; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; GAMMA BUTYROLACTONE; LIGNAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CLINICAL RESEARCH; CLOSTRIDIACEAE; DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; EVIDENCE BASED MEDICINE; FAECALIBACTERIUM; FECES MICROFLORA; HELICOBACTER HEPATICUS; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; LACHNOSPIRACEAE; MAMMOGRAPHY; MICROBIAL COMMUNITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PYROSEQUENCING; RISK REDUCTION; RUMINOCOCCACEAE; ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; COMPLICATION; DIET; FEMALE; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

4-BUTYROLACTONE; ANIMALS; BREAST NEOPLASMS; DIET; ESTROGENS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIGNANS; OBESITY;

EID: 84990955080     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-016-0734-z     Document Type: Article

References (77)

1. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22. doi:10.1016/j.ccr.2012.02.022.
2. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320–9. doi:10.1038/nm.2328.
3. Mezencev R, Švajdler M. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries. Breast Cancer. 2016: 1–11. doi: 10.1007/s12282-016-0716-1.
4. Saarinen NM, Wärri A, Airio M, Smeds A, Mäkelä S. Role of dietary lignans in the reduction of breast cancer risk. Mol Nutr Food Res. 2007;51:857–66. doi:10.1002/mnfr.200600240.
5. Tan T, Zhang K, Sun WC. Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population. Breast Cancer. 2016: 1–6. doi: 10.1007/s12282-016-0712-5.
6. Sekiro I, Gill N, Jogova M, Tam NM, Robertson ML, de Llanos R, et al. Salmonella SPI-1-mediated neutrophil recruitment during enteric colitis is associated with reduction and alteration in intestinal microbiota. Gut Microbes. 2010;1:30–41. doi:10.4161/gmic.1.1.10950.
7. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4:478–85. doi:10.1038/nri1373.
8. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115–8.
9. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915–20. doi:10.1126/science.1104816.
10. Yang YH, Wang XM, Huycke T, Moore DR, Lightfoot SA, Huycke MM. Colon macrophages polarized by commensal bacteria cause colitis and cancer through the bystander effect. Transl Oncol. 2013;6:596–606.
11. Lin A, Bik EM, Costello EK, Dethlefsen L, Haque R, Relman DA, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS One. 2013;8:e53838. doi:10.1371/journal.pone.0053838.
12. Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014;20:908–22. doi:10.3748/wjg.v20.i4.908.
13. Jobin C. Colorectal cancer: looking for answers in the microbiota. Cancer Discov. 2013;3:384–7. doi:10.1158/2159-8290.CD-13-0042.
14. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12. doi:10.1038/nrc3610.
15. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317–28. doi:10.1016/j.chom.2014.02.007.
16. Hill MJ, Drasar BS, Aries V, Crowther JS, Hawksworth G, Williams R. Bacteria and aetiology of cancer of large bowel. Lancet. 1971;297:95–100.
17. Hill MJ, Goddard P, Williams R. Gut bacteria and aetiology of cancer of the breast. Lancet. 1971;298:472–3.
18. Lewis R. Gut bacteria and aetiology of breast cancer. Lancet. 1971;298:822–3.
19. Britton KE, Brown NJ. Advances in renography in relation to radiology and radiotherapy. Proc R Soc Med. 1971;64:342.
20. Goedert JJ, Jones G, Hua X, Xu X, Yu GQ, Flores R, et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015;107:djv147. doi:10.1093/jnci/djv147.
21. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105:709–22. doi:10.1038/bjc.2011.254.
22. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012;104:326–39. doi:10.1093/jnci/djr531.
23. Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res. 2012;72:696–706. doi:10.1158/0008-5472.CAN-11-2507.
24. Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JV, Cauley JA, et al. Estrogen metabolism and breast cancer risk among postmenopausal women a case–cohort study within B~FIT. Carcinogenesis. 2014;35:346–55. doi:10.1093/carcin/bgt367.
25. Rinaldi S, Key TJ, Peeters PH, Lahmann PH, Lukanova A, Dossus L, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer. 2006;118:2832–9. doi:10.1002/ijc.21730.
26. Arslan AA, Koenig KL, Lenner P, Afanasyeva Y, Shore RE, Chen Y, et al. Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomark Prev. 2014;23:1290–7. doi:10.1158/1055-9965.EPI-14-0009.
27. Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res. 2013;15:1–14. doi:10.1186/bcr3416.
28. Gunter MJ, Xie XH, Xue XN, Kabat GC, Rohan TE, Wassertheil-Smoller S, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 2015;75:270–4. doi:10.1158/0008-5472.CAN-14-2317.
29. Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med. 2007;167:1837–44. doi:10.1001/archinte.167.17.1837.
30. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6. doi:10.1038/nature12506.
31. Bard JM, Luu HT, Dravet F, Michel C, Moyon T, Pagniez A, et al. Relationship between intestinal microbiota and clinical characteristics of patients with early stage breast cancer. FASEB J. 2015;29(914):2.
32. Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99:4632–40. doi:10.1210/jc.2014-2222.
33. Flores R, Shi JX, Fuhrman BJ, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med. 2012;10:253. doi:10.1186/1479-5876-10-253.
34. Minelli EB, Beghini AM, Vesentini S, Marchiori L, Nardo G, Cerutti R, et al. Intestinal microflora as an alternative metabolic source of estrogens in women with uterine leiomyoma and breast cancer. Ann N Y Acad Sci. 1990;595:473–9.
35. Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS, et al. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol. 1994;32:1238–45.
36. Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003;162:691–702. doi:10.1016/S0002-9440(10)63863-1.
37. Rao VP, Poutahidis T, Ge ZM, Nambiar PR, Boussahmain C, Wang YY, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 2006;66:7395–400. doi:10.1158/0008-5472.CAN-06-0558.
38. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–4.
39. Coletta PL, Müller AM, Jones EA, Mühl B, Holwell S, Clarke D, et al. Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood. 2004;103:1050–8. doi:10.1182/blood-2003-03-0707.
40. Lakritz JR, Poutahidis T, Mirabal S, Varian BJ, Levkovich T, Ibrahim YM, et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget. 2015;6:9387. doi:10.18632/oncotarget.3328.
41. Green JE, Shibata M, Yoshidome K, Liu ML, Jorcyk C, Anver MR, et al. The C3 (1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene. 2000;19:1020–7. doi:10.1038/sj.onc.1203280.
42. Kohlhapp F, Rodriguez A, Ulanov A, Alverdy J, Liu D, Guevara-Patiño J. Changes of intestinal microbiota in a murine model of metastatic breast cancer valeriy poroyko. Surg Infect. 2012:s23.
43. Lakritz JR, Poutahidis T, Levkovich T, Varian BJ, Ibrahim YM, Chatzigiagkos A, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int J Cancer. 2014;135:529–40. doi:10.1002/ijc.28702.
44. Attraplsi S, Mutlu E. Fecal microbiota composition in women in relation to factors that may impact breast cancer development. Am J Gastroenterol. 2014:S183.
45. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–16.
46. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr. 2000;27:24.
47. Zhu BT, Han GZ, Shim JY, Wen YJ, Jiang XR. Quantitative structure–activity relationship of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147:4132–50. doi:10.1210/en.2006-0113.
48. Adlercreutz H, Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem. 1980;13:231–44.
49. Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10:324–35. doi:10.1016/j.chom.2011.10.003.
50. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation. Clin Pharmacokinet. 2002;41:751–90.
51. Van Eldere J, Robben J, De Pauw G, Merckx R, Eyssen H. Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl Environ Microbiol. 1988;54:2112–7.
52. Crenshaw TL, Goldberg JP. Sexual pharmacology: drugs that affect sexual functioning. New York: WW Norton & Co; 1996.
53. Ward HA, Kuhnle GG. Phytoestrogen consumption and association with breast, prostate and colorectal cancer in EPIC Norfolk. Arch Biochem Biophys. 2010;501:170–5. doi:10.1016/j.abb.2010.05.018.
54. Mariat D, Firmesse O, Levenez F, Guimarăes VD, Sokol H, Dore J, et al. The firmicutes/bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123. doi:10.1186/1471-2180-9-123.
55. Sonestedt E, Wirfält E. Enterolactone and breast cancer: methodological issues may contribute to conflicting results in observational studies. Nutr Res. 2010;30:667–77. doi:10.1016/j.nutres.2010.09.010.
56. Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG, et al. Global metabolomics reveals urinary biomarkers of breast cancer in a MCF-7 xenograft mouse model. Metabolites. 2013;3:658–72. doi:10.3390/metabo3030658.
57. Setchell KD, Borriello SP, Gordon H, Lawson AM, Harkness R, Morgan DM, et al. Lignan formation in man—microbial involvement and possible roles in relation to cancer. Lancet. 1981;318:4–7.
58. Shapira I, Sultan K, Lee A, Taioli E. Evolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancy. ISRN Oncol. 2013;2013:693920. doi:10.1155/2013/693920.
59. Stuedal A, Gram IT, Bremnes Y, Adlercreutz H, Veierød MB, Ursin G. Plasma levels of enterolactone and percentage mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 2005;14:2154–9.
60. Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, et al. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Int J Cancer. 2012;130:1401–10. doi:10.1002/ijc.26157.
61. Mabrok HB, Klopfleisch R, Ghanem KZ, Clavel T, Blaut M, Loh G. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis. 2012;33:203–8. doi:10.1093/carcin/bgr256.
62. Penttinen P, Jaehrling J, Damdimopoulos AE, Inzunza J, Lemmen JG, van der Saag P, et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology. 2007;148:4875–86. doi:10.1210/en.2007-0289.
63. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4. doi:10.1038/nature07540.
64. Bradlow HL. Obesity and the gut microbiome: pathophysiological aspects. Horm Mol Biol Clin Investig. 2014;17:53–61. doi:10.1515/hmbci-2013-0063.
65. Bradlow HL, Sepkovic DW, Telang N, Tiwari R. Adipocyte-derived factor as a modulator of oxidative estrogen metabolism: implications for obesity and estrogen-dependent breast cancer. In Vivo. 2011;25:585–8.
66. Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 2015;27:27–40. doi:10.1016/j.ccell.2014.11.009.
67. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217–24. doi:10.1245/s10434-011-1814-0.
68. West NR, Kost SE, Martin SD, Milne K, Nelson BH, Watson PH. Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108:155–62. doi:10.1038/bjc.2012.524.
69. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? Cancer Res. 2007;67:847–50. doi:10.1158/0008-5472.CAN-06-3468.
70. Erdman SE, Poutahidis T. Gut bacteria and cancer. Biochim Biophys Acta. 2015;1856:86–90. doi:10.1016/j.bbcan.2015.05.007.
71. Ness RB, Cauley JA. Antibiotics and breast cancer—what’s the meaning of this? JAMA. 2004;291:880–1. doi:10.1001/jama.291.7.880.
72. Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, et al. Identification of a novel immunogenic HLA-A* 0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol. 2008;181:146–54.
73. Franchi L, Warner N, Viani K, Nuñez G. Function of nod-like receptors in microbial recognition and host defense. Immunol Rev. 2009;227:106–28. doi:10.1111/j.1600-065X.2008.00734.x.
74. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2:90–7. doi:10.1038/ncponc0081.
75. Velicer CM, Lampe JW, Heckbert SR, Potter JD, Taplin SH. Hypothesis: is antibiotic use associated with breast cancer? Cancer Causes Control. 2003;14:739–47.
76. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004;291:827–35. doi:10.1001/jama.291.7.827.
77. Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol. 2002;3:364–73.